Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

Phase 3  | ENROLLING

BRUIN CLL-321; NCT04666038

CLL/SLL

BTK Inhibitor


A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma*

NCT04666038
Key Inclusion Criteria
  • Confirmed diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) requiring therapy as defined by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria
  • Previously treated with a covalent BTK inhibitor
  • Eastern Cooperative Oncology Group (ECOG) status of 0-2
  • Absolute neutrophil count ≥0.75 × 109/L without granulocyte-colony stimulating factor support
  • Hemoglobin ≥8 g/dL not requiring transfusion support or growth factors within 14 days of cycle 1 day 1
  • Platelets ≥50 × 109/L not requiring transfusion support or growth factors within 14 days of cycle 1 day 1. If the investigator has chosen rituximab + bendamustine as the arm B treatment, platelets must be ≥75 × 109/L
  • AST and ALT ≤3.0 x upper limit of normal (ULN); total bilirubin ≤1.5 x ULN
  • Estimated creatinine clearance of ≥30 mL/min; ≥40 mL/min if the investigator has chosen bendamustine/rituximab as the arm B treatment
Key Exclusion Criteria
  • Known or suspected Richter's transformation at any time preceding enrollment
  • Ongoing drug-induced liver injury
  • Active uncontrolled autoimmune cytopenia or idiopathic thrombocytopenic purpura
  • Significant cardiovascular disease
  • History of allogeneic or autologous stem cell transplantation (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days
  • Active or ongoing hepatitis B or C infection
  • Known active cytomegalovirus (CMV) infection
  • Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
  • Known HIV infection, regardless of CD4 count
  • Clinically significant active malabsorption syndrome or inflammatory bowel disease
  • Prior exposure to a noncovalent (reversible) BTK inhibitor
  • Patients requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist
  • Current treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers and/or strong P-gp inhibitors
  • Vaccination with a live vaccine within 28 days prior to randomization
  • Patients with the following hypersensitivity:
    • Known hypersensitivity, including anaphylaxis, to any component or excipient of pirtobrutinib, idelalisib, and bendamustine
    • Prior significant hypersensitivity to rituximab
*
This clinical trial is being conducted globally.
Pirtobrutinib is administered 200 mg PO QD until progression or unacceptable toxicity. 
Idelalisib is administered 150 mg PO BID. 
§
Rituximab is administered intravenously (IV) as 8 total infusions. 
Bendamustine is administered 70 mg/m2 IV on days 1 and 2 of cycles 1-6. 
Rituximab is administered IV as 6 total infusions. 
Contact the Loxo Oncology at Lilly Clinical Trial Team

Visit www.clinicaltrials.gov for more information on this trial.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.